Drug Trial Radar · NCT01404923
Effectiveness of On-demand Meteospasmyl® Use in Irritable Bowel Syndrome (IBS)
Last checked: Nov 20, 2026Latest source record: Nov 4, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
436
Actual
Start
Dec 2009
Primary completion
Oct 2011
Study completion Oct 2011
Sponsor
- Lead sponsor
- Laboratoires Mayoly SpindlerIndustry
- Sponsor type
- Industry
- First posted
- Jul 28, 2011
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare the effectiveness of 2 IBS treatment strategies: * Strategy A = MeteoSpasmyl®, on-demand therapy * Strategy B = standard of care chosen by the physician
Conditions
- Irritable Bowel Syndrome
Interventions
anti spasmodic agentsDrug
best standard of care prescriptions
alverine citrate, simeticoneDrug
on-demand therapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Irritable Bowel Syndrome Quality Of Life Overall ScoreTime frame: Baseline and 6 months
- Percentage of Improvement of the Total IBSQoL ScoresTime frame: Baseline and 6 Months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.